NHS Long Term Plan 2020 - Partner Profile - Fotofinder Systems
Updated: Feb 3
Who are Fotofinder Systems?
The family-run company based in Bavaria, Germany, has been developing medical imaging systems since 1991. FotoFinder is the pioneer and leading manufacturer of imaging system for complete skin cancer prevention by means of Automated Total Body Mapping (ATBM), digital dermoscopy, in hair diagnostics, psoriasis documentation and imaging in aesthetics.
Our corporate mission is to visualize skin and make standardized photography in medical practice easy and intuitive. This is done by intelligently combining state-of-the-art technology with software, hardware and camera technology.
How has Fotofinder Systems improved outcomes for the NHS and patients?
FotoFinder has been providing its services to NHS since 2013 and it has improved early skin cancer detection and long-term patient survival in both NHS and private practice. But more importantly, we have also implemented AI (95% sensitivity and 82.5% specificity) and fully integrated Moleanalyzer pro service in the field of skin cancer diagnosis. The AI score is a perfect tool to support doctors in the risk assessment of melanocytic and non-melanocytic skin lesions. This new technology has improved diagnostic accuracy and appropriate treatments, confidence in diagnosis (reduce number of unnecessary primary referrals), patient care management and patient satisfaction by providing a simple and effective long-term patient management and an improved patient flow.
What has been your greatest achievement to date? And were there any measurable outcomes that accompanied this achievement?
FotoFinder is the world’s leading digital dermoscopy system and is the best Total Body Dermoscopy solution with highest quality and reliability for almost 30 years.
Our Automated Total Body Mapping (ATBM), substantially has reduced examination time in high-risk patient and helping doctors to document skin and moles over time with brilliant images which can often prove lifesaving. Total body mapping in combination with dermoscopy has proven to be the best method for monitoring high risk patients: e.g. with genetic predisposition like dysplastic nevus syndrome, transplant patients, patients with diagnosed skin cancer or tumour etc. Since, 70% of melanoma develop “de novo” and not from a pre-existing mole, the total body mapping with Bodyscan analysis is the best method for a comprehensive monitoring patient at high risk of developing skin cancer.
In addition; our unique universe dermoscope software designed for standardised documentation and compatible for Teledermatology. Several thousand doctors in more than 100 countries use FotoFinder in their daily practice and FotoFinder ATBM is the choice of Key Opinion Leaders (KOLs) worldwide such; as Dr Jonathan Bowling (UK), Dr Howard Stevens (UK), Prof. Giuseppe Argenziano (Italy), Dr Josep Malvehy/Dr. Susana Puig (Spain), Prof. Ashfaq Marghoob (USA), Prof. Peter Soyer (Australia), Prof. Robert Hunger (Switzerland), Dr Aimilios Lallas (Greece), Prof. Hofmann-Wellenhof (Austria), Prof. Philippe Bahadoran (France), Prof. Hanble (Germany), and many more worldwide.
How many organisations/clients currently utilise the service/solution across the UK?
More than 100 experts across UK use FotoFinder systems for total body mapping and we are proud to work with Melanoma UK, Royal Marsden Hospital (London), Hammersmith Hospital (London), Royal Glamorgan Hospital (Wales), Nuffield Health Oxford, University Hospital Limerick, Highgate private Hospital, Royal South Hants University Hospital (Southampton), HCA clinic (London), Spire Dunedin Hospital, Rivers Hospital, Stroud general Hospital, Manchester Royal Infirmary, Cheltenham General Hospital, South Infirmary Victoria Hospital, Withington Community Hospital, Circle bath Hospital, Nuffield health Glasgow Hospital, Jersey General Hospital, Leighton Hospital, Solihull Hospital, Spire Cambridge Lea Hospital and many more.
Is there anything you would like to make delegates aware of ahead of the NHS Long Term Plan 2020 conference on 29th April?
FotoFinder ATBM is the world benchmark when it comes to the management of high-risk patients for melanoma, allowing you to document and analyse skin and moles super-fast and with high accuracy.
Powered by FotoFinder artificial intelligence (AI), the ATBM workflow saves you time and produces brilliant images that help you to find new and changed lesions fast and easily. All ATBM systems intelligently combine Total Body Photography and dermoscopy. That is the FotoFinder standard for double safety in the earliest detection of skin cancer!
What do you feel are the key points delegates need to digest when considering a partnership with Fotofinder Systems?
The goal is not the early detection of skin cancer, but the earliest detection! FotoFinder helps you to document the entire skin and individual moles over time and to detect pathological changes as early as possible. Total body mapping together with dermoscopy increases the likelihood of long-term patient survival.
This will reduce substantial time and cost for NHS by reducing time of examination and number of unnecessary biopsy and excision respectively.
If you would like to learn more about Fotofinder Systems https://www.fotofinder-systems.com/